In 2000, the number of independent pharmacies grew by more than 200, according to the National Community Pharmacists Association, Alexandria, VA. Based on NCPA's definition of an independent pharmacy - single-store independent pharmacies, independent chains, pharmacy franchises and pharmacist-owned supermarket pharmacies - independent pharmacies now number 24,841, or 45% of the nation's total market of 55,011 pharmacies.
In 2000, the number of independent pharmacies grew by more than 200, according to the National Community Pharmacists Association, Alexandria, VA. Based on NCPA's definition of an independent pharmacy - single-store independent pharmacies, independent chains, pharmacy franchises and pharmacist-owned supermarket pharmacies - independent pharmacies now number 24,841, or 45% of the nation's total market of 55,011 pharmacies.
Independent pharmacies experienced double-digit overall sales growth in 2000, increasing 18% over the previous year to reach an average of $2.33 million per pharmacy, according to the preliminary data. Prescription sales revenues also grew, accounting for 83% ($1.932 million) of total average sales - also representing an 18% increase from the previous year.
The number of prescriptions dispensed annually by the average independent pharmacy grew to 50,711 - a 6.9% increase, or 3,283 prescriptions per pharmacy surveyed. Overall, independents dispensed 1.26 billion prescriptions in 2000, 44% of the total of 2.84 billion retail prescriptions dispensed in the United States.
Gross margins continued to decline as a percentage of sales from 24% in 1999 to 23.4% in 2000. In dollars, gross margin increased by 15% to $545,482 - the highest ever recorded in the survey.
"The preliminary results of the [survey] firmly support our assertion that independent pharmacy is back," commented NCPA President John Carson. "Independent pharmacies continue to experience nearly record growth in total sales, in terms of dollars and volume. Although margins remain tight, we see these as key indicators of the vitality of today's independent pharmacy." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.